Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5085693 | 1.00 | L3MBTL1 (0.49) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL1495136 | 1.00 | L3MBTL1 (0.49) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8952697 | 0.99 | L3MBTL1 (0.48) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8952567 | 0.99 | L3MBTL1 (0.48) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8952590 | 0.99 | L3MBTL1 (0.48) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8952589 | 0.99 | L3MBTL1 (0.48) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8952565 | 0.99 | L3MBTL1 (0.48) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8952580 | 0.99 | L3MBTL1 (0.48) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8952600 | 0.99 | L3MBTL1 (0.48) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8952621 | 0.88 | HSD17B10 (0.48) | L3MBTL1GAAHSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001032156-A2 | METHODS FOR TREATING FIBROPROLIFERATIVE DISEASES | DALHOUSIE UNIVERSITY (CA) | 2001-05-10 | — | — | WO | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| EP-0232438-A1 | Use of xanthine derivatives for host defense mechanism enhancement | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1987-08-19 | — | — | EP | claimed |
| EP-3242668-A1 | PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES | Imprimis Pharmaceuticals Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016111885-A1 | PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES | IMPRIMIS PHARMACEUTICALS, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2013159006-A1 | POLYMORPHS OF (S)-1-(4,4,6,6,6-PENTADEUTERO-5-HYDROXYHEXYL)-3,7-DIMETHYL-1H-PURINE-2,6(3H,7H)-DIONE | CONCERT PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2008118390-A2 | BIOMARKERS FOR DIAGNOSTIC AND THERAPEUTIC METHODS | WAYNE STATE UNIVERSITY (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118387-A2 | ERYTHROCYTE ATP-RELEASE MODULATORS | WAYNE STATE UNIVERSITY (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1583971-A2 | MODULATION OF DEUBIQUITINASE FAMILY MEMBERS | TopoTarget UK Limited (GB) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004064711-A2 | MODULATION OF DEUBIQUITINASE FAMILY MEMBERS | TOPOTARGET UK LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
| US-20030216414-A1 | Method for preventing tissue injury from hypoxia | CELL THERAPEUTICS,INC. | 2003-11-20 | — | — | US | disclosed |
| WO-1994015605-A1 | ACETAL OR KETAL SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994011370-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994011001-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994006431-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0584347-A1 | ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1993017684-A2 | ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| WO-1992007566-A2 | ANTIFUNGAL ACTIVITY OF AND PREVENTION OF DRUG INDUCED NEPHROTOXICITY BY METHYLXANTHINE ANALOGUES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0252487-B1 | PACKAGE CONTAINING DRUG COMBINATIONS FOR SUCCESSIVE ADMINISTRATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-08 | — | — | EP | disclosed |
| EP-0252487-A2 | Package containing drug combinations for successive administration | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216414-A1 | Method for preventing tissue injury from hypoxia | HIF1AN, LPCAT3, PLAAT2 | L3MBTL1 339/4885GAA 1199/4885HSD17B10 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.